Serum 14-3-3η is a Marker that Complements Current Biomarkers for the Diagnosis of RA: Evidence from a Meta-analysis

References

• Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, Birnbaum NS, Burmester GR, Bykerk VP, Cohen MD, et al. 2010. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 62(9):2569–81.
   PubMed Web of Science ®Google Scholar
• Aletaha D, Smolen JS. 2018. Diagnosis and management of rheumatoid arthritis: A review. Jama. 320:1360–72.
   PubMed Web of Science ®Google Scholar
• Carrier N, de Brum-fernandes AJ, Liang P, Masetto A, Roux S, Biln NK, Maksymowych WP, Boire G. 2020. Impending radiographic erosive progression over the following year in a cohort of consecutive patients with inflammatory polyarthritis: prediction by serum biomarkers. RMD Open. 6(1):e001191.
   PubMed Web of Science ®Google Scholar
• Carrier N, Marotta A, de Brum-fernandes AJ, Liang P, Masetto A, Ménard HA, Maksymowych WP, Boire G. 2016. Serum levels of 14-3-3η protein supplement C-reactive protein and rheumatoid arthritis-associated antibodies to predict clinical and radiographic outcomes in a prospective cohort of patients with recent-onset inflammatory polyarthritis. Arthritis Res Ther. 18(1):37.
   PubMedGoogle Scholar
• Dai B, Lei L, Liu. C. 2018. Diagnostic value of serum 14-3-3eta protein combined with anti-cyclic citrullinated peptide antibody on rheumatoid arthritis. J Clin Internal Med. 35:251–54.
   Google Scholar
• Gong X, Xu S-Q, Wu Y, Ma -C-C, Qi S, Liu W, Xu J-H. 2017. Elevated serum 14-3-3η protein may be helpful for diagnosis of early rheumatoid arthritis associated with secondary osteoporosis in Chinese population. Clin Rheumatol. 36(11):2581–87.
   PubMed Web of Science ®Google Scholar
• Guan SZ, Yang Y-Q, Bai X, Wang Y, Feng K-Q, Zhang H-J, Dong M, Yang H-W, Li H-Q. 2019. Serum 14-3-3η could improve the diagnostic rate of rheumatoid arthritis and correlates to disease activity. Ann Clin Lab Sci. 49:57–62.
   PubMed Web of Science ®Google Scholar
• Hammam N, Salah S, Kholef EF, Moussa EM, Marotta A. 2020. 14-3-3η Protein in serum and synovial fluid correlates with radiographic damage and progression in a longitudinal evaluation of patients with established rheumatoid arthritis. Mod Rheumatol. 30:664–670.
   PubMed Web of Science ®Google Scholar
• Hirata S, Marotta A, Gui Y, Hanami K, Tanaka Y. 2015. Serum 14-3-3η level is associated with severity and clinical outcomes of rheumatoid arthritis, and its pretreatment level is predictive of DAS28 remission with tocilizumab. Arthritis Res Ther. 17(1):280.
   PubMedGoogle Scholar
• Huang J, Zeng T, Zhang X, Tian Y, Wu Y, Yu J, Pei Z, Liu Y, Hu T, Tan L, et al. 2020. Clinical diagnostic significance of 14-3-3η protein, high-mobility group box-1, anti-cyclic citrullinated peptide antibodies, anti-mutated citrullinated vimentin antibodies and rheumatoid factor in rheumatoid arthritis. Br J Biomed Sci. 77(1):19–23.
   PubMed Web of Science ®Google Scholar
• Hyndman IJ. 2017. Rheumatoid arthritis: past, present and future approaches to treating the disease. Int J Rheum Dis. 20:417–19.
   PubMed Web of Science ®Google Scholar
• Kilani RT, Maksymowych WP, Aitken A, Boire G, St-Pierre Y, Li Y, Ghahary A. 2007. Detection of high levels of 2 specific isoforms of 14-3-3 proteins in synovial fluid from patients with joint inflammation. J Rheumatol. 34:1650–57.
   PubMed Web of Science ®Google Scholar
• Maksymowych WP, Boire G, van Schaardenburg D, Wichuk S, Turk S, Boers M, Siminovitch KA, Bykerk V, Keystone E, Tak PP, et al. 2015. 14-3-3η autoantibodies: diagnostic use in early rheumatoid arthritis. J Rheumatol. 42(9):1587–94.
   PubMed Web of Science ®Google Scholar
• Maksymowych WP, Marotta A. 2014. 14-3-3η: a novel biomarker platform for rheumatoid arthritis. Clin Exp Rheumatol. 32:S-35-9.
   PubMed Web of Science ®Google Scholar
• Maksymowych WP, Naides SJ, Bykerk V, Siminovitch KA, van Schaardenburg D, Boers M, Landewé R, van der Heijde D, Tak -P-P, Genovese MC, et al. 2014a. Serum 14-3-3η is a novel marker that complements current serological measurements to enhance detection of patients with rheumatoid arthritis. J Rheumatol. 41(11):2104–13.
   PubMed Web of Science ®Google Scholar
• Maksymowych WP, van der Heijde D, Allaart CF, Landewé R, Boire G, Tak PP, Gui Y, Ghahary A, Kilani R, Marotta A, et al. 2014b. 14-3-3η is a novel mediator associated with the pathogenesis of rheumatoid arthritis and joint damage. Arthritis Res Ther. 16(2):R99.
   PubMed Web of Science ®Google Scholar
• Manolova I, Ivanova M, Vasilev G, Stoilov R, Miteva L, Stanilova S. 2020. Impact of IL12B polymorphisms on genetic susceptibility and IL-12p40 and IL-23 serum levels in rheumatoid arthritis. Immunol Invest. 49(1–2):1–14.
   PubMed Web of Science ®Google Scholar
• Marotta A, Maksymowych WP. 2014. Levels of 14-3-3eta predict good EULAR response to anti-TNF treatment in patients with rheumatoid arthritis. Ann Rheum Dis. 73:615.3–616.
   Google Scholar
• Naides SJ, Marotta A. 2015. 14-3-3η in “seronegative” rheumatoid arthritis. J Rheumatol. 42:1995.
   PubMedGoogle Scholar
• Pratt AG, Isaacs JD. 2014. Seronegative rheumatoid arthritis: pathogenetic and therapeutic aspects. Best Pract Res Clin Rheumatol. 28:651–59.
   PubMed Web of Science ®Google Scholar
• Sakr BR, Elfishawi MM, ElArousy MH, Hatw AK, AbdulKarim AN, Tammam AB, Kotp AN, Hamed ME, Genedy IE, Desouky EDE, et al. 2018. Rheumatoid arthritis: A single-center Egyptian experience. Immunol Invest. 47:293–302.
   PubMed Web of Science ®Google Scholar
• Samimi Z, Izadpanah A, Feizollahi P, Roghani SA, Assar S, Zafari P, Taghadosi M. 2020. The association between the plasma sugar and lipid profile with the gene expression of the regulatory protein of mTOR (Raptor) in patients with rheumatoid arthritis. Immunol Invest. 1–12. doi:https://doi.org/10.1080/08820139.2020.1781160
   Google Scholar
• Shovman O, Gilburd B, Watad A, Amital H, Langevitz P, Bragazzi NL, Adawi M, Perez D, Bornstein G, Grossman C, et al. 2018. The diagnostic value of 14-3-3η protein levels in patients with rheumatoid arthritis. Best Pract Res Clin Rheumatol. 32(4):610–17.
   PubMed Web of Science ®Google Scholar
• Shovman O, Gilburd B, Watad A, Amital H, Langevitz P, Bragazzi NL, Adawi M, Perez D, Lidar M, Katz I, et al. 2019. Decrease in 14-3-3η protein levels is correlated with improvement in disease activity in patients with rheumatoid arthritis treated with Tofacitinib. Pharmacol Res. 141:623–26.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Aletaha D, McInnes IB. 2016. Rheumatoid arthritis. Lancet. 388(10055):2023–38.
   PubMed Web of Science ®Google Scholar
• Sparks JA. 2019. Rheumatoid Arthritis. Ann Intern Med. 170:Itc1–itc16.
   PubMed Web of Science ®Google Scholar
• Tan L, Wang Q, Zeng T, Long T, Guan X, Wu S, Zheng W, Fu H, Meng Y, Wu Y, et al. 2018. Clinical significance of detecting HLA-DR, 14-3-3η protein and d-dimer in the diagnosis of rheumatoid arthritis. Biomark Med. 12(7):697–705.
   PubMed Web of Science ®Google Scholar
• van Beers-tas MH, Marotta A, Boers M, Maksymowych WP, van Schaardenburg D. 2016. A prospective cohort study of 14-3-3η in ACPA and/or RF-positive patients with arthralgia. Arthritis Res Ther. 18(1):76.
   PubMedGoogle Scholar
• Van Schaardenburg D, Murphy M, Gui Y, Turk S, Maksymowych WP, Marotta A. 2014. Change in 14-3-3η expression in early RA patients treated with DMARDS corresponds with change in DAS28 and good Eular responses. Arthritis Rheumatol. 66:S837–S838.
   Web of Science ®Google Scholar
• Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, Leeflang MM, Sterne JA, Bossuyt PM. 2011. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med. 155:529–536.
   PubMed Web of Science ®Google Scholar
• Zeng T, Tan L, Wu Y, Yu J. 2020. 14-3-3eta protein in rheumatoid arthritis: promising diagnostic marker and independent risk factor for osteoporosis. Laboratory medicine. Lab Med 51: 529–539.
   Google Scholar
• Zeng T, Tan. L. 2018. 14-3-3η protein: a promising biomarker for rheumatoid arthritis. Biomark Med. 12:917–25.
   PubMed Web of Science ®Google Scholar
• Zeng TT, Tan LM, Chen JJ, Jiang YQ. 2017. Clinical significance of serum 14-3-3η protein and auto-antibodies detection in rheumatoid arthritis. Chin J Immunol. 33:1689–1693.
   Google Scholar
• Zhang Y, Liang Y, Feng L, Cui L. 2020. Diagnostic performance of 14-3-3η and anti-carbamylated protein antibodies in Rheumatoid Arthritis in Han population of Northern China. Clin Chim Acta. 502:102–110.
   PubMed Web of Science ®Google Scholar
• Zhao J, Li. ZG. 2018. The challenges of early diagnosis and therapeutic prediction in rheumatoid arthritis. Int J Rheum Dis. 21:2059–62.
   PubMed Web of Science ®Google Scholar